From Me to We

The Scientist Community is about to take off. We hope you'll join us.

Written byRichard Gallagher
| 3 min read

Register for free to listen to this article
Listen with Speechify
0:00
3:00
Share

This is my page. Here, I get to talk every month about whatever I want. I like that.

The editorial staff (there's half-a-dozen besides me) decide what's going to be in the magazine each month, and what stories we are going to report on the Web site every day. We like that too.

But things could be a lot - a whole lot - more interesting.

What if, instead of being a passive consumer of The Scientist, our readers played a role in shaping the content? We could have 700, or 7,000, minds thinking up and debating great story ideas, instead of just seven. Such a community could identify breakthrough research and commercialization opportunities before they received widespread attention. Or decide on the fields and firms that are being oversold. It could identify scandals, tag the unrecognized heroes and geniuses of science and business, and work out and test ways ...

Interested in reading more?

Become a Member of

The Scientist Logo
Receive full access to digital editions of The Scientist, as well as TS Digest, feature stories, more than 35 years of archives, and much more!
Already a member? Login Here

Meet the Author

Published In

Share
February 2026

A Stubborn Gene, a Failed Experiment, and a New Path

When experiments refuse to cooperate, you try again and again. For Rafael Najmanovich, the setbacks ultimately pushed him in a new direction.

View this Issue
Human-Relevant In Vitro Models Enable Predictive Drug Discovery

Advancing Drug Discovery with Complex Human In Vitro Models

Stemcell Technologies
Redefining Immunology Through Advanced Technologies

Redefining Immunology Through Advanced Technologies

Ensuring Regulatory Compliance in AAV Manufacturing with Analytical Ultracentrifugation

Ensuring Regulatory Compliance in AAV Manufacturing with Analytical Ultracentrifugation

Beckman Coulter Logo
Conceptual multicolored vector image of cancer research, depicting various biomedical approaches to cancer therapy

Maximizing Cancer Research Model Systems

bioxcell

Products

Sino Biological Logo

Sino Biological Pioneers Life Sciences Innovation with High-Quality Bioreagents on Inside Business Today with Bill and Guiliana Rancic

Sino Biological Logo

Sino Biological Expands Research Reagent Portfolio to Support Global Nipah Virus Vaccine and Diagnostic Development

Beckman Coulter

Beckman Coulter Life Sciences Partners with Automata to Accelerate AI-Ready Laboratory Automation

Refeyn logo

Refeyn named in the Sunday Times 100 Tech list of the UK’s fastest-growing technology companies